Indications
Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone
Composition
- Active substance
- somatrogon
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ngenla
- Active substance
- somatrogon
- ATC code
- H01AC08
- Therapeutic area
- Growth and Development
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Status
- Authorised
- EU authorisation
- 14 Feb 2022